The morning surge of blood pressure (BP) is associated with ␣-adrenergic activity. We studied the association between the ␣-adrenergic morning surge in BP and silent cerebrovascular disease in elderly patients with hypertension. Methods: We conducted ambulatory BP monitoring three times (twice at baseline and after nighttime dosing of the ␣ 1 -blocker doxazosin) in 98 elderly hypertensive patients in whom the presence of silent cerebral infarcts (SCI) was assessed by brain magnetic resonance imaging. The morning BP surge (MBPS) was calculated as the mean systolic BP during the 2 h after waking minus the mean systolic BP during 1 h that included the lowest sleep BP. The ␣-adrenergic MBPS was calculated as the reduction of MBPS by doxazosin. Results: The prevalence of multiple SCI was higher in the Surge group (top quartile: MBPS Ն45 mm Hg, n ϭ 24) than in the Nonsurge group (MBPS Ͻ45 mm Hg, n ϭ 74) (54% v 31%, P ϭ .04), and in the higher ␣-adrenergic
C
ardiovascular events occur more commonly in the morning than at other times of day, and the diurnal blood pressure (BP) variation also shows a peak early in the morning. 1, 2 We have recently clarified that the morning BP surge is risk for stroke events independently of 24-h BP level in elderly individuals with hypertension. 3 It is generally accepted that the sympathetic nervous system plays a major role in the regulation of BP changes, and therefore an increase in ␣-adrenergic activity might be one of the major determinants of this morning BP surge. 4 In fact, the Hypertension and Lipid Trial (HALT) study disclosed that the BP reduction with an ␣-blocker, doxazosin, was most pronounced in the morning period. 5, 6 Furthermore, it is also possible that the morning increase in ␣-adrenergic activity and related BP surge contribute to the morning peak of cardiovascular events.
There is some evidence indicating that aging is associated with increased sympathetic nervous activity 7 and that central nervous system mechanisms mediate this process. 8 This systemic increase in sympathetic activity in older subjects might be expected to cause or to exacerbate hypertension and cardiac and vascular hypertrophy. 9, 10 Autonomic dysfunction, which is mainly related to increased sympathetic activity, is frequently present in pa-tients with clinical cerebrovascular disease. 11, 12 In elderly persons with hypertension, silent cerebral infarcts (SCI) are commonly found and are one of the strongest predictors of strokes. 13 However, the associations between the morning increase in ␣-adrenergic activity and the related BP surge with silent hypertensive target organ damage have not been thoroughly investigated.
To study the association between the morning BP surge (particularly the component associated with ␣-adrenergic activity) and silent cerebrovascular disease, we investigated the effect of nighttime dosing of doxazosin on the morning BP surge using ambulatory BP monitoring (ABPM) in asymptomatic elderly hypertensive individuals, with or without SCI detected by brain magnetic resonance imaging (MRI).
Methods

Patient Selection
This was an open-label study of the effects of doxazosin on ambulatory BP, which included older Japanese hypertensive patients at three Japanese hospital clinics. The entry period was June 1996 to January 2001. A total of 106 patients who were either untreated or were off medication for at least 1 week at the time of entry were studied. The entry BP criterion was Ն140 mm Hg for an average of a seated clinic systolic BP (SBP) or Ն90 mm Hg for diastolic BP (DBP) during the follow-up period (3 to 5 weeks). To be included in the study, patients had to be Ն60 years of age, to have a diagnosis of essential hypertension, and to have no history of other significant medical disorders including diabetes or any clinically overt cardiovascular disease. All participants were fully ambulant.
Body mass index was calculated as weight (kg)/height (m) 2 . Electrocardiographically verified left ventricular hypertrophy was defined by abnormally high voltages of QRS complexes (R in V5 plus S in V1 Ͼ3.5 mV) associated either with flat T waves (Ͻ10% of R) or with ST segment depression and biphasic T waves.
Study Design
Each patient was studied for a maximum of 11 weeks, with an observation period of 3 to 5 weeks, a titration period of up to 4 weeks, and 1 to 5 weeks of maintenance therapy. After the observation period, patients were started on 1 mg doxazosin daily, taken at bedtime. The dose was doubled at weekly intervals until the average seated BP had fallen 1) by at least 20/10 mm Hg from the baseline level, or 2) by at least 10/5 mm Hg from the baseline level when baseline BP was Ͻ160/90 mm Hg. If BP reduction reached the above criteria at each of two consecutive visits, if a maximal daily dose of 8 mg doxazosin had been reached, or if adverse effects had occurred, no further dose increase was attempted. After the titration phase there was a maintenance phase of 1 to 5 weeks on the same dose of doxazosin. This protocol was modified from that of the HALT study. 5, 6 Informed consent was obtained from all subjects, and the study was approved by the Research Ethical Committee of Department of Cardiology, Jichi Medical School.
We excluded three patients for whom at least one of the three BP recordings was not evaluable because of the presence of artifacts in Ͼ20% of either awake or asleep measurements. One patient who refused a second ABPM and two patients who reported that their sleep was severely disturbed by the ABPM were also excluded from the analysis. Two patients who developed orthostatic dizziness (one during the observation period and one during the titration period) were also discontinued from the study. Accordingly, three complete sets of ABPM data were successfully obtained in 98 patients.
Ambulatory BP Monitoring
Noninvasive ABPM was carried out three times on a weekday with one of two automatic ABPM devices (TM-2421 or TM-2425; A&D Co. Inc., Tokyo, Japan), which recorded BP and pulse rate by the oscillometric method every 30 min for 24 h. The accuracy of these devices was previously validated. The first ABPM was performed at the time of entry after being unmedicated for at least 2 weeks, the second ABPM at the end of the drug-free baseline period (3 to 5 weeks), and the third at the end of the maintenance period (1 to 5 weeks). The interval between the first and second ABPM and between the second and third ABPM were 3 to 5 weeks and 4 to 6 weeks, respectively.
We defined 24-h BP as the average of all BP readings throughout 24 h. All subjects were ambulant during the day, and none reported staying in bed after waking. Sleep BP was defined as the average of BP from the time when patients went to bed until the time they got out of bed, and awake BP as the average of BP recorded during the rest of the day. Morning BP was defined as the average of BP during the first 2 h after waking (four BP readings). The lowest BP was defined as the average BP of three readings centered on the lowest nighttime reading (that is, the lowest reading plus the readings immediately before and after). Evening BP was defined as the average BP during the 2 h before going to bed (four BP readings). Preawake BP was defined as the average BP during the 2 h just before waking (four BP readings). The morning BP surge (MBPS) was calculated as the morning SBP minus the lowest SBP. Systolic pressures were used for all of these calculations. We subclassified the patients according to the extent of the MBPS as follows: the top quartile of MBPS (Ն45 mm Hg, n ϭ 24, the Surge group), versus all others (n ϭ 74, the Nonsurge group). The ␣-adrenergic MBPS was calculated as the baseline MBPS (the average of the first and second MBPS) minus the third MBPS (during doxazosin therapy).
Brain MRI
Brain MRI was performed using a superconducting magnet with a main strength of 1.5 T (Toshiba MRT200FXII, Toshiba, Tokyo, Japan; SIGNA-Horizon version 5.8, General Electric Co.; or Vision, Siemens, Munich, Germany) during the period of Յ3 months before the first ABPM and the initiation of doxazosin treatment after the second ABPM. T1-and T2-weighted images were obtained in the transverse plane with sections 7.8 mm or 8.0 mm thick. An SCI was defined as a low signal intensity area (3 to 15 mm) on T1-weighted images that was also visible as a hyperintense lesion on T2-weighted images, as previously described. [13] [14] [15] Multiple SCI was defined as two or more infarcts. All SCI detected were lacunar infarcts of Ͻ15 mm. The MRI images of the subjects were randomly stored and interpreted by a professional blind to the subjects' names and characteristics. The statistics assessing inter-reader and intrareader agreement (non-SCI, one SCI, and multiple SCI) were 0.70 and 0.80, respectively, in our laboratory.
Statistical Analysis
The analysis was conducted using data from the 98 patients in whom brain MRI and three ambulatory BP recordings were successfully obtained. The changes from the baseline values were analyzed statistically using paired t tests for each subgroup. Two-sided unpaired t tests and 2 tests were used to test differences between the two groups in the mean values of continuous measures and prevalence rates, respectively. One-way analysis of covariance (ANCOVA) (controlling for age, sex, body mass index, smoking status, hyperlipidemia, duration of hypertension, dose of doxazosin, and 24-h systolic BP) were performed to detect differences among groups. Spearman correlation coefficients were calculated. Adjusted odds ratios (OR) and 95% confidence intervals (CI) of the presence of multiple SCI (two or more per person) versus single SCI or no SCI per person was calculated using multiple logistic regression analysis (multiple SCI ϭ 1, one or no SCI ϭ 0). Multiple linear regression analysis was used to test the differences in the slope of the relationship of MBPS and ␣-adrenergic MBPS between patients with and without multiple SCI. The criterion for determining statistical significance was P Ͻ .05. Results are given as mean Ϯ SD. Figure 1 shows the ambulatory BP values during the two baseline recordings and after doxazosin therapy. Nighttime dosing of doxazosin reduced morning BP more effectively than the other ambulatory BP parameters. There was no significant effect of doxazosin on the lowest SBP at night. 
Results
Ambulatory BP
Morning BP Surge
At baseline, the average MBPS was 33 Ϯ 16 mm Hg for SBP and 17 Ϯ 8.3 mm Hg for SBP (the average of the first and the second ABPM data), and the correlation coefficients between MBPS calculated from the first ABPM and the second ABPM were 0.66 for SBP and 0.42 for DBP (both P Ͻ .0001). The ␣-adrenergic MBPS (reduction of MBPS by doxazosin) was 13 Ϯ 17 mm Hg for SBP and 3.4 Ϯ 12 mm Hg for DBP. The ␣-adrenergic MBPS was significantly correlated with the baseline MBPS (r ϭ 0.73, P Ͻ .001; Fig. 2 ).
The Surge group had significantly higher prevalences of left ventricular hypertrophy, multiple SCI, and number of SCI than the Nonsurge group (all P Ͻ .05), whereas the age and clinic and 24-h BP levels were comparable between the two groups (Table 1 ). Even after adjusting for possible confounding factors (age, sex, body mass index, smoking status, hyperlipidemia, duration of hypertension, dose of doxazosin, and 24-h systolic BP), the higher prevalence of multiple SCI in the Surge group remained significant (P Յ .05; Table 2 ). Both the MBPS (P Ͻ .05) and ␣-adrenergic MBPS (P Ͻ .001) were significantly associated with the number of SCI ( Table 3 ). The ␣-adrenergic MBPS was significantly associated with smoking (P Ͻ .01) but with not with age or body mass index.
Silent Cerebral Infarction
The prevalence of multiple SCI was higher in the Surge group (top quartile: MBPS Ն 45 mm Hg, n ϭ 24) than in the Nonsurge group (MBPS Ͻ 45 mm Hg, n ϭ 74) (54% v 31%, P ϭ .04). Those with the highest ␣-adrenergic MBPS (top quartile: ␣-adrenergic MBPS Ն28 mm Hg, n ϭ 25) had a higher prevalence of SCI (68% v 34%, P ϭ .005) and multiple SCI (68% v 26%, P Ͻ .0001) than those with a lower ␣-adrenergic MBPS (␣-adrenergic MBPS Ͻ28 mm Hg, n ϭ 73). In the Surge group, those with higher ␣-adrenergic MBPS (n ϭ 17) had a markedly higher frequency of multiple SCI, whereas none in the lower ␣-adrenergic Surge group had multiple SCI (n ϭ 7) (77% v 0%, P ϭ .001; Fig. 2 ). In addition, the slope between MBPS and ␣-adrenergic MBPS (Fig. 2) was significantly steeper in patients with multiple SCI than in those without multiple SCI, even after controlling for 24-h BP (P Ͻ .05). Table 4 shows the results of adjusted MBPS and ␣-adrenergic MBPS using ANCOVA. Even after adjusting for possible confounding variables, MBPS and ␣-adrenergic MBPS were significantly higher in the multiple SCI group than in the nonmultiple SCI group. Table 5 shows the results of a logistic regression analysis using MBPS and ␣-adrenergic MBPS as continuous variables in the total sample. After adjusting for possible confounding variables, both MBPS (model 1) and ␣-adrenergic MBPS (model 2) were significantly associated with multiple SCI. However, when both were entered in the same model (model 3), only ␣-adrenergic MBPS remained significant. These surges were also significantly associated with SCI (one ore more SCI per person: 10 mm Hg MSBP increase: OR ϭ 1.44, P ϭ .03; 10 mm Hg ␣-adrenergic MBPS increase: OR ϭ 1.55, P ϭ .006). There were no significant associations between the morning surge in pulse rate and either single or multiple SCI.
Discussion
This study, has demonstrated a positive association between the MBPS, particularly the component associated with ␣-adrenergic activity, and silent hypertensive cerebrovascular disease in elderly individuals. This finding is supported by the relatively high reproducibility of MBPS in the two baseline recordings, and the fact that we used the average of these to reduce regression to the mean when assessing the effects of the ␣-adrenergic blocking drug doxazosin.
Morning BP Surge
The Surge group in this study had a higher number of SCI and higher prevalence of multiple SCI than the Nonsurge group, whereas there was no significant difference in the clinic and average 24-h BP between the two groups. In addition, when we considered the MBPS as a continuous variable, MBPS was significantly correlated with the number of SCI independent of other possible confounders including 24-h SBP level. These results indicate that factors other than persistent BP overload may be involved in the progression of SCI in hypertensive individuals. The SCI occurs predominantly in the small cerebral vessels. An excessive morning BP surge might facilitate microvascular remodeling in the small cerebral arteries through increased shear stress. In addition, platelets may be acti- Data shown as mean Ϯ SE or percentages after adjusting for age, sex, body mass index, smoking status, hyperlipidemia, duration of hypertension, daily dose of doxazosin, and 24-h systolic blood pressure using analysis of covariance. vated by increased shear stress 16 and by increased sympathetic tone (an ␣ 2 -receptor mediated effect). 17 Thus, in atherosclerotic arteries, platelet activation in the morning hours could contribute to the formation of microthrombus.
Determinants of Alpha Adrenergic Morning BP Surge
We defined the ␣-adrenergic component of the MBPS as the reduction of MBPS by doxazosin therapy. The ␣-adrenergic MBPS varied widely among individual patients, even within the MS group, suggesting that the mechanism of MBPS is heterogeneous. The function of the human sympathetic nervous system is altered in important ways by aging. Microneurographic recording from sympathetic fibers and studies of spillover of the sympathetic neurotransmitter norepinephrine to plasma suggest that progressive sympathetic activation occurs with aging, 7 although the sympathetic ␣-adrenergic vasoconstrictor responsiveness to endogenous norepinephrine release has been found to be reduced with age in healthy men. 18 Thus ␣ 1 -adrenergic blocker therapy might be especially useful for elderly hypertensive patients whose BP level is predominantly dependent on increased sympathetic activity. In fact, the previous results of the HALT study indicated that the doxazosin was more effective in older than in younger hypertensive persons.
7,8
Alpha Adrenergic Morning BP Surge and Cerebrovascular Disease
The ␣-adrenergic MBPS was positively associated with the number of SCI in the multiple logistic regression analysis, independently of age, 24-h BP, and other confounding variables. A general characteristic of antihypertensive drugs is that the greater the baseline BP level, the greater the BP reduction. Thus the ␣-adrenergic morning BP surge, defined by the BP response to doxazosin, would partly depend on the baseline morning BP surge level. The morning surge is not exclusively mediated by the ␣-adrenergic sympathetic system, as it can also be controlled by a nonspecific, appropriately timed intervention such as extended release verapamil. 19 However, in our study, the difference in the slopes of the baseline morning BP surge and the BP response to doxazosin (Fig. 2) between subjects with multiple SCI and those without multiple SCI may indicate that there is some ␣-adrenergic role in the pathogenesis of silent hypertensive cerebrovascular disease. In addition, when we entered the MBPS and ␣-adrenergic MBPS into the same model, only the ␣-adrenergic MBPS remained significantly correlated with SCI. In the Surge group, subjects with higher ␣-adrenergic surge had a markedly higher frequency of multiple SCI, whereas none in the lower ␣-adrenergic Surge group had multiple SCI. Because this was a cross-sectional study, the causal relationships between the various factors remain unclear. Increased sympathetic activity could accelerate the progression of SCI formation through increased morning BP surge and other pathways such as platelet hyperactivation, endothelial cell dysfunction, and increased blood viscosity. 1,2 On the other hand, the presence of multiple SCI might itself increase the morning BP surge by altering central sympathovagal balance toward increased sympathetic activity. Thus sympathetic activity is increased in patients with clinically overt ischemic cerebrovascular disease, as manifested by increased plasma norepinephrine levels, which may be an independent risk factor for future cardiovascular and cerebrovascular events. 12 In a study using muscle sympathetic nervous activity recording, sympathetic nervous activity was higher in the patients with cerebrovascular disease than in control subjects, suggesting that the damage of cortical or subcortical structures might cause an increase in basal sympathetic activity. 10 In our previous study, heart rate variability, an indicator of autonomic nervous function, was diminished in hypertensive patients with multiple SCI.
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Study Limitation
This study lacks specific data for other antihypertensive drugs. The renin-angiotensin system, 21 which also exhibits a morning surge, 22 could also contribute to the BP surge. Thus, angiotensin converting enzyme inhibitors or angiotensin receptor blockers, particularly if administered to patients just before they go to bed, may suppress the morning BP surge. Labetalol, 23 an ␣/␤ blocker, and extended-release verapamil taken at bedtime 19 also blunt the morning BP surge. Because our data suggest that the morning surge in sympathetic activity may have detrimental effects, it is possible that patients may benefit from treatments that inhibit this surge, either by central or peripheral blockade of the ␣-adrenergic limb of the sympathetic nervous system. At the same time it should be borne in mind that in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), the rate of hospitalization for congestive heart failure was doubled in patients in the doxazosin arm compared with the chlorthalidone arm, 24 and there was also a slightly higher risk of stroke. However, the latter difference could be explained by the lower BP levels in the chlorthalidone group. In reality, most patients who are taking and ␣-blocker for lowering their BP are likely to be taking a diuretic as well.
In conclusion, our study suggests that an increased morning surge in BP, particularly that dependent on ␣-adrenergic activity, may be linked to the development of hypertensive cerebrovascular disease.
